Guiding Model-driven Combination Dose Selection Using Multi-objective Synergy Optimization

Overview

Journal CPT Pharmacometrics Syst Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2023 Jul 7

PMID 37415306

Authors

Jana L Gevertz

Irina Kareva

Affiliations

Soon will be listed here.

Abstract

Despite the growing appreciation that the future of cancer treatment lies in combination therapies, finding the right drugs to combine and the optimal way to combine them remains a nontrivial task. Herein, we introduce the Multi-Objective Optimization of Combination Synergy - Dose Selection (MOOCS-DS) method for using drug synergy as a tool for guiding dose selection for a combination of preselected compounds. This method decouples synergy of potency (SoP) and synergy of efficacy (SoE) and identifies Pareto optimal solutions in a multi-objective synergy space. Using a toy combination therapy model, we explore properties of the MOOCS-DS algorithm, including how optimal dose selection can be influenced by the metric used to define SoP and SoE. We also demonstrate the potential of our approach to guide dose and schedule selection using a model fit to preclinical data of the combination of the PD-1 checkpoint inhibitor pembrolizumab and the anti-angiogenic drug bevacizumab on two lung cancer cell lines. The identification of optimally synergistic combination doses has the potential to inform preclinical experimental design and improve the success rates of combination therapies. Jel classificationDose Finding in Oncology.

Citing Articles

Improving neuroendocrine tumor treatments with mathematical modeling: lessons from other endocrine cancers.

Metzcar J, Guenter R, Wang Y, Baker K, Lines K Endocr Oncol. 2025; 5(1):e240025.

PMID: 39949335 PMC: 11825163. DOI: 10.1530/EO-24-0025.

Mitigating non-genetic resistance to checkpoint inhibition based on multiple states of immune exhaustion.

Kareva I, Gevertz J NPJ Syst Biol Appl. 2024; 10(1):14.

PMID: 38336968 PMC: 10858190. DOI: 10.1038/s41540-024-00336-6.

Role of pharmacometrics and systems pharmacology in facilitating efficient dose optimization in oncology.

Jayachandran P, Desikan R, Krishnaswami S, Hennig S CPT Pharmacometrics Syst Pharmacol. 2023; 12(11):1569-1572.

PMID: 37849052 PMC: 10681474. DOI: 10.1002/psp4.13066.

Guiding model-driven combination dose selection using multi-objective synergy optimization.

Gevertz J, Kareva I CPT Pharmacometrics Syst Pharmacol. 2023; 12(11):1698-1713.

PMID: 37415306 PMC: 10681518. DOI: 10.1002/psp4.12997.

References

Koch G, Schropp J, Jusko W . Assessment of non-linear combination effect terms for drug-drug interactions. J Pharmacokinet Pharmacodyn. 2016; 43(5):461-79. PMC: 5439368. DOI: 10.1007/s10928-016-9490-0. View

Moon H . FDA initiatives to support dose optimization in oncology drug development: the less may be the better. Transl Clin Pharmacol. 2022; 30(2):71-74. PMC: 9253446. DOI: 10.12793/tcp.2022.30.e9. View

Lederer S, Dijkstra T, Heskes T . Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition. Front Pharmacol. 2018; 9:31. PMC: 5808155. DOI: 10.3389/fphar.2018.00031. View

Palmer A, Sorger P . Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. Cell. 2017; 171(7):1678-1691.e13. PMC: 5741091. DOI: 10.1016/j.cell.2017.11.009. View

Banavali S, Pasquier E, Andre N . Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma. Ecancermedicalscience. 2015; 9:499. PMC: 4303616. DOI: 10.3332/ecancer.2015.499. View

Shah M, Rahman A, Theoret M, Pazdur R . The Drug-Dosing Conundrum in Oncology - When Less Is More. N Engl J Med. 2021; 385(16):1445-1447. DOI: 10.1056/NEJMp2109826. View

Kareva I . A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells. Int J Mol Sci. 2017; 18(10). PMC: 5666816. DOI: 10.3390/ijms18102134. View

Wooten D, Meyer C, Lubbock A, Quaranta V, Lopez C . MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery. Nat Commun. 2021; 12(1):4607. PMC: 8322415. DOI: 10.1038/s41467-021-24789-z. View

Vlot A, Aniceto N, Menden M, Ulrich-Merzenich G, Bender A . Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls. Drug Discov Today. 2019; 24(12):2286-2298. DOI: 10.1016/j.drudis.2019.09.002. View

10.

Zsiros E, Lynam S, Attwood K, Wang C, Chilakapati S, Gomez E . Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2020; 7(1):78-85. PMC: 7677872. DOI: 10.1001/jamaoncol.2020.5945. View

11.

Ma J, Motsinger-Reif A . Current Methods for Quantifying Drug Synergism. Proteom Bioinform. 2020; 1(2):43-48. PMC: 7010330. View

12.

Meyer C, Wooten D, Paudel B, Bauer J, Hardeman K, Westover D . Quantifying Drug Combination Synergy along Potency and Efficacy Axes. Cell Syst. 2019; 8(2):97-108.e16. PMC: 6675406. DOI: 10.1016/j.cels.2019.01.003. View

13.

Gevertz J, Kareva I . Guiding model-driven combination dose selection using multi-objective synergy optimization. CPT Pharmacometrics Syst Pharmacol. 2023; 12(11):1698-1713. PMC: 10681518. DOI: 10.1002/psp4.12997. View

14.

Chowdhury P, Chamoto K, Honjo T . Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. J Intern Med. 2017; 283(2):110-120. DOI: 10.1111/joim.12708. View

15.

Dudek A, Liu L, Gupta S, Logan T, Singer E, Joshi M . Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003. J Clin Oncol. 2020; 38(11):1138-1145. PMC: 7145584. DOI: 10.1200/JCO.19.02394. View

16.

Harshe I, Enderling H, Brady-Nicholls R . Predicting Patient-Specific Tumor Dynamics: How Many Measurements Are Necessary?. Cancers (Basel). 2023; 15(5). PMC: 10000065. DOI: 10.3390/cancers15051368. View

17.

Meyer C, Wooten D, Lopez C, Quaranta V . Charting the Fragmented Landscape of Drug Synergy. Trends Pharmacol Sci. 2020; 41(4):266-280. PMC: 7986484. DOI: 10.1016/j.tips.2020.01.011. View

18.

Jaaks P, Coker E, Vis D, Edwards O, Carpenter E, Leto S . Effective drug combinations in breast, colon and pancreatic cancer cells. Nature. 2022; 603(7899):166-173. PMC: 8891012. DOI: 10.1038/s41586-022-04437-2. View

19.

Roell K, Reif D, Motsinger-Reif A . An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines. Front Pharmacol. 2017; 8:158. PMC: 5397413. DOI: 10.3389/fphar.2017.00158. View

20.

Chou T . Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2):440-6. DOI: 10.1158/0008-5472.CAN-09-1947. View